Wesley Buckingham
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study.
Journal: ESMO real world data and digital oncology
Published: February 06, 2026
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 19, 2025
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy.
Journal: Nature communications
Published: May 23, 2025
Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.
Journal: Journal of the National Cancer Institute
Published: March 11, 2025
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab.
Journal: NPJ breast cancer
Published: September 28, 2024
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer.
Journal: ESMO open
Published: August 15, 2024
HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 13, 2024
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.
Journal: ESMO open
Published: December 24, 2023
The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients.
Journal: NPJ breast cancer
Published: September 27, 2019
Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
Journal: Clinical breast cancer
Published: July 23, 2019
The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer.
Journal: Breast cancer research : BCR
Published: March 19, 2018
Last Updated: 09/26/2026